Evidence map›Paper›PMID 27255140›Full record

ArticleJIMD reports2016

Identification of Cryptic Novel α-Galactosidase A Gene Mutations: Abnormal mRNA Splicing and Large Deletions.

Takashi Higuchi, Masahisa Kobayashi, Jin Ogata, Eiko Kaneshiro, Yohta Shimada, Hiroshi Kobayashi, Yoshikatsu Eto, Shiro Maeda, Akira Ohtake, Hiroyuki Ida and 1 more

Abstract read
In one paragraph

Article in JIMD reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Takashi HiguchiDivision of Gene Therapy, Research Center for Medical Sciences, The Jikei University School of Medicine, Tokyo, Japan. tahiguchi@jikei.ac.jp.
Masahisa KobayashiDepartment of Pediatrics, The Jikei University School of Medicine, Tokyo, Japan.
Jin OgataDepartment of Pediatrics, The Jikei University School of Medicine, Tokyo, Japan.
Eiko KaneshiroDepartment of Pediatrics, The Jikei University School of Medicine, Tokyo, Japan.
Yohta ShimadaDivision of Gene Therapy, Research Center for Medical Sciences, The Jikei University School of Medicine, Tokyo, Japan.
Hiroshi KobayashiDivision of Gene Therapy, Research Center for Medical Sciences, The Jikei University School of Medicine, Tokyo, Japan.
Yoshikatsu EtoFront-Line Clinic Center, Kanagawa, Japan.
Shiro MaedaDepartment of Advanced Genomic and Laboratory Medicine, Faculty of Medicine, University of the Ryukyus, Okinawa, Japan.
Akira OhtakeDepartment of Pediatrics, Saitama Medical University, Saitama, Japan.
Hiroyuki IdaDivision of Gene Therapy, Research Center for Medical Sciences, The Jikei University School of Medicine, Tokyo, Japan.
Toya OhashiDivision of Gene Therapy, Research Center for Medical Sciences, The Jikei University School of Medicine, Tokyo, Japan. tohashi@jikei.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anderson-Fabry (FD) disease is an inborn error of metabolism caused by a deficiency of α-galactosidase A (GLA), a lysosomal enzyme. Many male FD patients display a classic FD phenotype; however, some female patients have neither reduced leukocyte GLA enzyme activity level nor FD symptoms. Thus, GLA gene analysis is especially important for diagnosing suspected FD in female subjects. In this study, we revealed 4 novel GLA gene mutations in 5 independent families using GLA cDNA analysis and multiplex ligation-dependent probe amplification (MLPA) analysis. These distinct mutations included a large deletion mutation from intron 1 to exon 5 (c.195-471_c.691del5.5k, corresponding to g.8508_g.14069del5.5k), an insertion mutation of splicing enhancer sequence in intron 4 (c.639+329_c.639+330ins113, corresponding to g.12627_g.12628ins113), an insertion mutation of retrotransposon L1 in exon 4 (c.634_c.635, corresponding to g.12293_g.12294), and a non-SNP deep intronic point mutation in intron 3 (c.547+395G>C, corresponding to g.11727G>C). It is difficult to detect these mutations with direct sequencing of only the exonic element. When exonic mutations are not found in the GLA gene from suspected FD patients, GLA cDNA and MLPA analyses should be performed to detect large deletion/insertion and intronic mutations including transcription abnormalities.

Identifiers

PMID27255140
PMCPMC5110446

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.